Bifidobacterium longum subsp. longum BG-L47 boosts growth and activity of Limosilactobacillus reuteri DSM 17938 and its extracellular membrane vesicles
Ludwig Ermann LundbergiD, Punya Pallabi MishraiD, Peidi LiuiD, Manuel Mata ForsbergiD, Eva Sverremark‐EkströmiD, Gianfranco GromponeiD, Sebastian HåkanssoniD, Caroline LinningeiD, Stefan RoosiD
Abstract
The aim was to identify a Bifidobacterium strain that improved the performance of Limosilactobacillus reuteri DSM 17938. Initial tests showed that Bifidobacterium longum subsp. longum strains boosted the growth of DSM 17938 during in vivo-like conditions. Further characterization revealed that one of the strains, BG-L47, had better bile and acid tolerance compared to BG-L48, as well as mucus adhesion compared to both BG-L48 and the control strain BB536. BG-L47 also had the capacity to metabolize a broad range of carbohydrates and sugar alcohols. Mapping of glycoside hydrolase (GH) genes of BG-L47 and BB536 revealed many GHs associated with plant-fiber utilization. However, BG-L47 had a broader phenotypic fiber utilization capacity. In addition, B. longum subsp. longum cells boosted the bioactivity of extracellular membrane vesicles (MV) produced by L. reuteri DSM 17938 during cocultivation. Secreted 5 nucleotidase (5NT), an enzyme that converts AMP into the signal molecule adenosine, was increased in MV boosted by BG-L47. The MV exerted an improved antagonistic effect on the pain receptor TRPV1 and increased the expression of the immune development markers IL-6 and IL-1{beta} in a PBMC model. Finally, the safety of BG-L47 was evaluated both by genome safety assessment and in a human safety study. Microbiota analysis showed that the treatment did not induce significant changes in the composition. In conclusion, B. longum subsp. longum BG-L47 has favorable physiological properties, can boost the in vitro activity of L. reuteri DSM 17938, and is safe for consumption, making it a candidate for further evaluation in probiotic studies. ImportanceBy using probiotics that contain a combination of strains with synergistic properties, the likelihood of achieving beneficial interactions with the host can increase. In this study, we first performed a broad screening of Bifidobacterium longum subsp. longum strains in terms of synergistic potential and physiological properties. We identified a superior strain, BG-L47, with favorable characteristics and potential to boost the activity of the known probiotic strain Limosilactobacillus reuteri DSM 17938. Further, we demonstrated that BG-L47 is safe for consumption in a human randomized clinical study and by performing a genome safety assessment. This work illustrates that bacteria-bacteria interactions differ at the strain level and further provides a strategy for finding and selecting companion strains of probiotics.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 10
- FWCI
- 1.66
- Field percentile
- top 20%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel bacteriocin produced by Bifidobacterium longum subsp. infantis has dual antimicrobial and immunomodulatory activity
S. G. Javvadi, M. Kujawska, … L. J. Hall·bioRxiv·Jan 27, 2022
- Evolutionary changes of an intestinal Lactobacillus reuteri during probiotic manufacture
L. Lopez, P. A. Cardenas, … G. Trueba·bioRxiv·Mar 5, 2019
- Biocompatible Membrane Vesicles from Lactobacillus acidophilus MTCC 10307 Exhibit Potent Anti-Inflammatory Activity
Venkatramanan Mahendrarajan, Nalini Easwaran·bioRxiv·Apr 3, 2026
- Strain-specific alterations in gut microbiome and host immune responses elicited by Bifidobacterium pseudolongum
B. Ma, S. J. Gavzy, … J. S. Bromberg·bioRxiv·Mar 16, 2022
- Genetically-programmed Hypervesiculation of Lactiplantibacillus plantarum Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model
Nicholas H. Pirolli, Daniel H. Levy, … Steven M. Jay·Advanced SciencePeer-reviewed·Nov 26, 2025
- Limosilactobacillus reuteri promotes the expression and secretion of enteroendocrine- and enterocytederived hormones
Sara C. Di Rienzi, Heather A. Danhof, … Robert A. Britton·The FASEB JournalPeer-reviewed·Mar 18, 2025